Summary This latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster - Pipeline Review, H2 2020, provides an overview of the Herpes Zoster (Infectious Disease) pipeline landscape.
Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Herpes Zoster (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Herpes Zoster (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Herpes Zoster (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Herpes Zoster (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Herpes Zoster (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Infectious Disease)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The Europe organoids market is projected to reach US$ 1,260.08 million by 2027 from US$ 247.85 million in 2019; it is estimated to grow at a CAGR of 22.5% from 2020 to 2027. Increasing demand for tumor modelling and biobanking and rising adoption of personalized drugs are expected to drive the market. Personalized medicine is a growing...
The Middle East & Africa organoids market is expected to reach US$ 141.26 million in 2027 from US$ 37.34 million in 2019; the market is estimated to grow at a CAGR of 20.9% from 2020 to 2027. The growth of the market can be attributed to growing research on organoids in the Middle East & Africa region and rising focus on developing alternatives...
The North America organoids market is expected to reach US$ 1,406.47 million by 2027 from US$ 291.39 million in 2019. The market is anticipated to grow at a CAGR of 21.7% from 2020 to 2027. Growth of the North America organoids market is attributed to emergence of three-dimensional (3D) organoids and rise in investments in research. However,...
The South and Central America nurse call systems market is expected to reach US$ 200.11 million by 2027 from US$ 87.23 million in 2019. The market is estimated to grow at a CAGR of 10.8% from 2020-2027. The growth of the South and Central America nurse call systems market is driven by the growing incidence of Alzheimer’s disease and dementia...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
Digital Pathology Market Size, Share & Trends Analysis Report By Product (Software, Device), By Application (Drug Discovery & Development, Academic Research), By End-use, By Region, And Segment Forecasts, 2021 - 2028 Digital Pathology Market Growth & Trends The global digital pathology market...
KEY FINDINGS The global disposable patient positioning products market is anticipated to register a CAGR of 3.21%, during the forecast years of 2021 to 2028. The primary market growth drivers include the growing volume of surgeries, the rise in the geriatric population, and the surging investments across the healthcare...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Therapy
Pathology
Probiotics
Autoimmune Disease
Infectious Disease
APAC
World
Europe
Central America
Health Expenditure
Diabetes Prevalence
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.